Search company, investor...
Bionure company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Series A | Alive

Total Raised


Last Raised

$4.72M | 4 yrs ago

About Bionure

Bionure is a biotech company developing first - in - class SGK agonists for the treatment of different neurodegenerative disorders for which no treatment options are nowadays available.

Bionure Headquarters Location

Parc Científic de Barcelona Torres R+D+I, Baldiri Reixac 4-8

Barcelona, 08028,


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Bionure

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Bionure is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Bionure Patents

Bionure has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Prodrugs, Experimental cancer drugs, Monoclonal antibodies, Transcription factors, Proteins


Application Date


Grant Date



Related Topics

Prodrugs, Experimental cancer drugs, Monoclonal antibodies, Transcription factors, Proteins



Latest Bionure News

‘No new safety concerns’ emerge for ocrelizumab in MS subpopulations

Sep 10, 2021

Disclosures: Hauser reports serving on the board of trustees for Neurona and on scientific advisory boards for Alector, Annexon, Bionure and Molecular Stethoscope, as well as having received travel reimbursement and writing assistance from F. Hoffmann-La Roche Ltd. and Novartis for CD20 related meetings and presentations. Please see the study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact . Back to Healio Continuous administration of ocrelizumab in clinical trials and its broader use in real-world settings exhibited a favorable and manageable safety profile for relapsing MS and primary progressive MS, according to a study in Neurology. Prior phase 2 and 3 studies outlined the safety and efficacy of ocrelizumab, leading to its approval for treating these patient populations; however, adverse events occurred. Infographic data derived from: Hauser SL, et al. Neurology. 2021;doi:10.1212/WNL.0000000000012700. “In controlled treatment periods of the pivotal phase 3 trials, infusion-related reactions, respiratory tract infections and urinary tract infections were the most common adverse events associated with [ocrelizumab],” study author Stephen L. Hauser, MD, of the department of neurology at the University of California, San Francisco, and colleagues wrote. “A numerical imbalance of malignancies was observed in patients treated with OCR relative to its comparators, mostly driven by a higher rate of breast cancer; overall, these events were uncommon. Safety surveillance to understand the long-term benefit–risk profile of OCR in patients with MS (PwMS) is therefore warranted.” In the current analysis, the investigators reported the safety profile of ocrelizumab for up to 7 years among patients with relapsing MS and primary progressive MS who participated in clinical trials or received treatment in real-world post-marketing settings. They based safety analyses on integrated clinical and laboratory data of all patients who received ocrelizumab in 11 clinical trials, which included the controlled treatment and open-label extension periods of the phase 2 and 3 trials, as well as seven phase 3b trials. Further, they used additional post-marketing data for selected adverse events. The researchers used multiple epidemiologic sources to contextualize incidence rates of serious infections and malignancies. Hauser and colleagues used a data cut-off date of January 2020 and included data of 5,680 patients with MS, with 18,218 who received ocrelizumab in clinical trials, with 18,218 patient-years of exposure. Results showed similar rates per 100 person years in the current analysis compared with those within the controlled treatment period of the phase 3 trials for adverse events (248), serious adverse events (7.3), infusion-related reactions (25.9) and infections (76.2). The researchers noted consistency between ranges reported in epidemiologic data and rates of the most common serious adverse events, including serious infections (2.01) and malignancies (0.46). “No new safety concerns have emerged in a heterogeneous MS population (in more recent clinical trials and real-world settings) that includes early treatment-naive patients with relapsing-remitting multiple sclerosis, patients with [relapsing MS] previously treated with other [disease-modifying therapies (DMTs)], and patients with active secondary progressive [MS] or [primary progressive MS] who are older, more disabled and have a longer DMT history and higher number of comorbidities,” Hauser and colleagues wrote. “Long-term follow-up and post-marketing studies will continue to monitor the safety of long-term treatment with [ocrelizumab] in increasing numbers of patients.” Read more about

  • Where is Bionure's headquarters?

    Bionure's headquarters is located at Parc Científic de Barcelona, Barcelona.

  • What is Bionure's latest funding round?

    Bionure's latest funding round is Series A.

  • How much did Bionure raise?

    Bionure raised a total of $4.72M.

  • Who are the investors of Bionure?

    Investors of Bionure include Alta Life Sciences.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.